Why the study?
Does Ramipril reduce the risk of future cardiovascular events in high-risk patients without low ventricular ejection fraction or heart failure?
Does Ramipril reduce the risk of future cardiovascular events in high-risk patients without low ventricular ejection fraction or heart failure?
The HOPE study demonstrated that Ramipril safely and cost-effectively reduces cardiovascular events in high-risk patients without heart failure, establishing its role in cardiovascular prevention.
Answers are grounded in this paper and cite their sources.
Supports ramipril for high-risk prevention; leaves open applicability in contemporary cohorts with modern therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
McQueen et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: